2025
127 Analytical Validation and Prospective Study of a High-Sensitivity HER2 (HS-HER2) Quantitative Immunofluorescence Assay for Enhanced Stratification of HER2-Low Breast Cancer Patients
Chan N, Gaule P, Benanto J, Robbins C, Scott L, Hill S, Morrison R, Liebler D, Fulton R, Rimm D. 127 Analytical Validation and Prospective Study of a High-Sensitivity HER2 (HS-HER2) Quantitative Immunofluorescence Assay for Enhanced Stratification of HER2-Low Breast Cancer Patients. Laboratory Investigation 2025, 105: 102351. DOI: 10.1016/j.labinv.2024.102351.Peer-Reviewed Original ResearchSocial support, fear of cancer recurrence and sleep quality in breast cancer: A moderated network analysis
Jiang Y, Wu X, Li H, Xiong Y, Knobf M, Ye Z. Social support, fear of cancer recurrence and sleep quality in breast cancer: A moderated network analysis. European Journal Of Oncology Nursing 2025, 74: 102799. PMID: 39842318, DOI: 10.1016/j.ejon.2025.102799.Peer-Reviewed Original ResearchFear of cancer recurrenceSocial supportSleep qualityPittsburgh Sleep Quality Index scalePerceived Social Support ScaleLevels of social supportEffect of social supportModerating effect of social supportHigh social supportSocial Support ScaleGeneralized anxietyBreast cancerCancer recurrenceCancer patientsSleep efficiencySupport ScaleMental healthBreast cancer patientsIndex scaleSleep problemsBuffering factorsJohnson-NeymanAnxietyFearSupport
2024
Association Between Delayed/Forgone Medical Care and Resource Utilization Among Women with Breast Cancer in the United States
Reddy K, Jarrell K, Berkowitz C, Hulse S, Elmore L, Fishman R, Greenup R, Mateo A, Rothman J, Sataloff D, Tchou J, Zafar S, Fayanju O. Association Between Delayed/Forgone Medical Care and Resource Utilization Among Women with Breast Cancer in the United States. Annals Of Surgical Oncology 2024, 32: 2534-2544. PMID: 39694997, PMCID: PMC11882630, DOI: 10.1245/s10434-024-16586-x.Peer-Reviewed Original ResearchConceptsBreast cancer careCancer careEmergency departmentBreast cancerWeighted proportion of patientsMedical Expenditure Panel SurveyPrescription medication expendituresOffice-based encountersProportion of patientsOffice-based visitsOut-of-pocketAssociated with increased resource utilizationChi-square testRao-ScottFinancial barriersHealthcare expendituresInpatient expendituresMedical careHealthcare spendingBreast cancer patientsMedical expendituresCareUnited StatesResource utilizationPanel SurveyAssessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patients
Generali D, Rocca A, Strina C, Milani M, Fiorino E, Cervoni V, Azzini C, Saracino A, Ciliberto I, Ziglioli N, Alberio M, Giudici F, Dester M, Ciani O, Fornaro G, Aguggini S, Dreezen C, Pronin D, Ende S. Assessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patients. Heliyon 2024, 10: e39485. PMID: 39553665, PMCID: PMC11564935, DOI: 10.1016/j.heliyon.2024.e39485.Peer-Reviewed Original ResearchLow-risk tumorsHigh-risk tumorsRisk tumorsOverall survivalBreast cancerFollow-upPrognostic performanceHigh-risk BC patientsIntermediate-risk breast cancerLong-term prognostic abilitySingle-center prospective cohort studyPathologic tumor characteristicsProgesterone receptor-positiveSingle-center prospective cohortMedian follow-upBreast cancer patientsGenomic riskProspective cohort studyCox regression modelsPersonalize treatment choicesNodal statusReceptor statusReceptor-positiveTumor characteristicsTumor sizeModeling epithelial-mesenchymal transition in patient-derived breast cancer organoids
Bar-Hai N, Ben-Yishay R, Arbili-Yarhi S, Herman N, Avidan-Noy V, Menes T, Mansour A, Awwad F, Balint-Lahat N, Goldinger G, Hout-Siloni G, Adileh M, Berger R, Ishay-Ronen D. Modeling epithelial-mesenchymal transition in patient-derived breast cancer organoids. Frontiers In Oncology 2024, 14: 1470379. PMID: 39469640, PMCID: PMC11513879, DOI: 10.3389/fonc.2024.1470379.Peer-Reviewed Original ResearchEpithelial-mesenchymal transitionPatient-derived breast cancer modelsCancer patientsCell plasticityTGF-bBreast cancer organoidsCancer cell plasticityBreast cancer modelBreast cancer patientsEMT-like featuresE-cadherin downregulationEMT-like processCancer modelsOrganoid linesCancer organoidsEpithelial plasticityInvasive phenotypeCellular plasticityE-cadherinOrganoidsPatientsCancerDedifferentiation processMorphological changesCytoskeletal reorganizationPredicting Radiation-Induced Acute Toxicity in Breast Cancer Patients: A Radiogenomic Approach
Wei S, Zhang Y, Sowmiyanarayanan S, Yehia Z, Jan I, Yue N, Haffty B, Nie K. Predicting Radiation-Induced Acute Toxicity in Breast Cancer Patients: A Radiogenomic Approach. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e341. DOI: 10.1016/j.ijrobp.2024.07.752.Peer-Reviewed Original ResearchBreast cancer patientsRadiation dermatitisSide effectsCancer patientsBreast cancer patients treated with radiationRadiogenomic approachCancer patients treated with radiationRadiation-induced acute toxicityPatients treated with radiationRadiomic featuresSingle nucleotide polymorphismsAcute radiation dermatitisBreast-conserving surgeryRadiation side effectsPeripheral blood samplesTotal radiation dosePersonalized treatment strategiesGenetic statusRadiation therapyMammographic patternsRadiomic texture featuresTherapy side effectsClinical parametersRetrospective studyClinical featuresClinical Outcomes in Breast Cancer Patients with Underlying Germline PALB2 Mutations Treated with Radiation
Shalaby A, Jan I, Ohri N, Yehia Z, Toppmeyer D, Haffty B. Clinical Outcomes in Breast Cancer Patients with Underlying Germline PALB2 Mutations Treated with Radiation. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e331-e332. DOI: 10.1016/j.ijrobp.2024.07.731.Peer-Reviewed Original ResearchBreast-conserving surgeryPALB2 variantsBreast cancer patientsInterpretations of pathogenicityClinical outcomesPathogenic variantsHypo-RTBreast cancer patients treated with radiationCancer patients treated with radiationCancer patientsRisk of radiation toxicitySentinel lymph node dissectionPatients treated with radiationMedical recordsPALB2 pathogenic variantsContralateral breast cancerExternal beam radiationMedian tumor sizeLymph node dissectionSuppression of cancer developmentGrade 2 fibrosisRecurrence 4 monthsMultigene panel testingDNA double-strand break repairDouble-strand break repairArtificial-Intelligence Cloud-Based Platform to Support Shared Decision-Making in the Locoregional Treatment of Breast Cancer: Protocol for a Multidimensional Evaluation Embedded in the CINDERELLA Clinical Trial
Borsoi L, Listorti E, Ciani O. Artificial-Intelligence Cloud-Based Platform to Support Shared Decision-Making in the Locoregional Treatment of Breast Cancer: Protocol for a Multidimensional Evaluation Embedded in the CINDERELLA Clinical Trial. PharmacoEconomics - Open 2024, 8: 945-959. PMID: 39264499, PMCID: PMC11499581, DOI: 10.1007/s41669-024-00519-1.Peer-Reviewed Original ResearchBreast cancer patientsBackgroundShared decision-makingBreast cancer careCloud-based approachPatient decision aidsMultidimensional evaluationCloud-based platformReduce decision regretCost-utility analysisCancer patientsCancer carePatient-level dataHealthcare professionalsArtificial-intelligenceMobile applicationsPersonalized contentDecision regretCountry-specific unit costsFocus groupsLocoregional treatmentPatient questionnaireDecision aidPatient valuationsReal-world settingsWeb platformPTCOG international survey of practice patterns and trends in utilization of proton therapy for breast cancer
Choi J, Hardy-Abeloos C, Lozano A, Hanlon A, Vargas C, Maduro J, Bradley J, Offersen B, Haffty B, Pankuch M, Amos R, Kim N, MacDonald S, Kirova Y, Mutter R. PTCOG international survey of practice patterns and trends in utilization of proton therapy for breast cancer. Clinical And Translational Radiation Oncology 2024, 48: 100847. PMID: 39280125, PMCID: PMC11399555, DOI: 10.1016/j.ctro.2024.100847.Peer-Reviewed Original ResearchProton beam therapyBreast cancer patientsParticle Therapy Co-Operative GroupPatient selection methodsBreast cancerCancer patientsTreat breast cancer patientsRegional nodal irradiationFisher's exact testSurvey of practice patternsModerate hypofractionationNodal irradiationRadiation oncologistsBeam therapyPBT patientsProton therapyExact testU.S. centersDescriptive statisticsEuropean centersPractice patternsPatientsResponding centersBreastAsian centersComparison of incident breast cancer cases in the largest national US tumor registries
Plichta J, Thomas S, Chanenchuk T, Chan K, Hyslop T, Hwang E, Greenup R. Comparison of incident breast cancer cases in the largest national US tumor registries. Cancer 2024, 131: e35525. PMID: 39154223, PMCID: PMC11695170, DOI: 10.1002/cncr.35525.Peer-Reviewed Original ResearchIncident breast cancer casesUS Cancer StatisticsBreast cancer casesNational Cancer DatabaseNon-HispanicNon-Hispanic American Indian/Alaska NativesCancer casesTumor RegistryIn situ breast cancerPopulation cancer registryNon-Hispanic blacksSamples of breast cancer patientsNon-Hispanic whitesAmerican Indian/Alaska NativeEnd Results ProgramBreast cancerPacific IslandersCancer RegistryCancer statisticsIndian/Alaska NativeCase ascertainmentInterpretation of findingsResults ProgramBreast cancer patientsRegistryThe black box of the relationship between breast cancer patients and accompanying patients: the accompanied patients’ point of view
Pomey M, Iliescu Nelea M, Vialaron C, Normandin L, Côté M, Desforges M, Pomey-Carpentier P, Adjtoutah N, Fortin I, Ganache I, Régis C, Rosberger Z, Charpentier D, Bélanger L, Dorval M, Ghadiri D, Lavoie-Tremblay M, Boivin A, Pelletier J, Fernandez N, Danino A, de Guise M. The black box of the relationship between breast cancer patients and accompanying patients: the accompanied patients’ point of view. BMC Cancer 2024, 24: 822. PMID: 38987731, PMCID: PMC11234724, DOI: 10.1186/s12885-024-12585-z.Peer-Reviewed Original ResearchConceptsSemi-structured interviewsCare trajectoryClinical teamBreast cancer patientsCare trajectory of peopleMethodsA qualitative studyEmotional well-beingQuality of lifeEnhance overall qualityCancer patientsResultsThree themesHealth professionalsPatient experienceHealthcare professionalsProvince of QuebecPatient communicationPatients' perceptionsEmotional reassuranceThematic analysisHealthcare systemUniversity Medical CenterQualitative studyPatient's pointTrajectories of peopleReduce anxietyClinicopathologic Characteristics of MYC Copy Number Amplification in Breast Cancer
Sun T, Golestani R, Zhan H, Krishnamurti U, Harigopal M, Zhong M, Liang Y. Clinicopathologic Characteristics of MYC Copy Number Amplification in Breast Cancer. International Journal Of Surgical Pathology 2024, 33: 59-64. PMID: 38839260, DOI: 10.1177/10668969241256109.Peer-Reviewed Original ResearchBreast cancerCopy number amplificationClinicopathological characteristicsAssociation with <i>TP53</i> mutation. InAssociated with invasive ductal carcinomaEstrogen receptor (ER)-negativeDisease-free survival timeGene copy number amplificationC-myc immunostainingNon-amplified tumorsTP53</i> mutationsTriple-negative statusMetastatic breast cancerInvasive ductal carcinomaMYC protein overexpressionBreast cancer patientsTriple-negativeDuctal carcinomaClinicopathological featuresGenetic abnormalitiesClinical dataImmunohistochemical studiesCancer patientsProtein overexpressionSurvival timePredicting peripheral neuropathy following neoadjuvant therapy in patients with breast cancer.
Feiger B, Biancalana M, Shelton A, Blenman K, Lustberg M. Predicting peripheral neuropathy following neoadjuvant therapy in patients with breast cancer. Journal Of Clinical Oncology 2024, 42: e12639-e12639. DOI: 10.1200/jco.2024.42.16_suppl.e12639.Peer-Reviewed Original ResearchBreast cancer patientsNeoadjuvant chemotherapyPeripheral neuropathyNeoadjuvant therapyBreast cancerCancer patientsAdministration of neoadjuvant chemotherapyCohort of breast cancer patientsLikelihood of breast-conserving surgeryContrast-enhanced magnetic resonance imagingQuality of lifeDynamic contrast-enhanced magnetic resonance imagingBreast-conserving surgeryReduced tumor burdenTreatment-induced neuropathyOccurrence of neuropathyInduce peripheral neuropathyDensity of blood vesselsPatients' quality of lifeMagnetic resonance imagingAmeliorate neuropathyDCE-MRI dataTumor burdenCumulative toxic effectsIntratumoral vascularityCINDERELLA clinical trial: Using artificial intelligence–driven healthcare to enhance breast cancer locoregional treatment decisions.
Bonci E, Kaidar-Person O, Antunes M, Ciani O, Cruz H, Di Micco R, Gentilini O, Heil J, Kabata P, Romariz M, Gonçalves T, Martins H, Borsoi L, Mika M, Pfob A, Romem N, Schinkoethe T, Silva G, Bobowicz M, Cardoso M. CINDERELLA clinical trial: Using artificial intelligence–driven healthcare to enhance breast cancer locoregional treatment decisions. Journal Of Clinical Oncology 2024, 42: tps621-tps621. DOI: 10.1200/jco.2024.42.16_suppl.tps621.Peer-Reviewed Original ResearchPatient expectationsQuality of lifeResults post-interventionPatient-centred careCancer patients' expectationsBreast cancer expertsOverall quality of lifeImprove patient satisfactionWeighted Cohen's kappaPsychological well-beingBreast cancer treatmentPost-interventionNon-metastatic breast cancer patientsWilcoxon signed-rank testApp contentClinical study sitesLocoregional treatment decisionsCancer expertsBreast cancer patientsPatient satisfactionSigned-rank testPatient informationAesthetic outcomesEligibility criteriaOutcome levelA phase Ib/II study of an anti-CD137 agonist antibody ADG106 in combination with weekly paclitaxel and dose-dense doxorubicin/cyclophosphamide.
Lee M, Ow S, Wong A, Lim S, Lim J, Soo R, Cheng Ean C, Tan D, Yong W, Chan G, Ho J, Sooi K, Low Q, Ang C, Cheo S, Sundar R, Goh B, Lee S. A phase Ib/II study of an anti-CD137 agonist antibody ADG106 in combination with weekly paclitaxel and dose-dense doxorubicin/cyclophosphamide. Journal Of Clinical Oncology 2024, 42: e14507-e14507. DOI: 10.1200/jco.2024.42.16_suppl.e14507.Peer-Reviewed Original ResearchAdverse eventsG3 neutropeniaTumor biopsiesWeekly PPeripheral neuropathyHER2 negative breast cancer patientsPhase IbDose levelsRecommended phase 2 doseAll-grade adverse eventsNegative breast cancer patientsMatched tumor biopsiesPhase 2 doseTumor immune markersPneumocystis jiroveci pneumoniaAdvanced solid tumorsPalliative systemic therapyPhase Ib trialPhase II trialPhase IISerial tumor biopsiesBreast cancer patientsIgG4 monoclonal antibodyAcneiform rashAnti-CD137Ultra-sensitive ctDNA mutation tracking to identify molecular residual disease and predict relapse in patients with early breast cancer.
Garcia-Murillas I, Cutts R, Abbott C, Boyle S, Pugh J, Chen R, Dunne K, Bunce C, Johnston S, Ring A, Russell S, Evans A, Skene A, Wheatley D, Smith I, Turner N. Ultra-sensitive ctDNA mutation tracking to identify molecular residual disease and predict relapse in patients with early breast cancer. Journal Of Clinical Oncology 2024, 42: 1010-1010. DOI: 10.1200/jco.2024.42.16_suppl.1010.Peer-Reviewed Original ResearchMolecular residual diseaseCirculating tumor DNAEarly breast cancerBreast cancer patientsFollow-upNeoadjuvant chemotherapyResidual diseaseClinical relapseCtDNA detectionClinical outcomesBreast cancerAssociated with relapse free survivalDetection of molecular residual diseaseCancer patientsCirculating tumor DNA levelsLevels of circulating tumor DNAHigh risk of relapseHigh riskCirculating tumor DNA detectionMedian lead-timeRelapse free survivalDe-escalation studiesBreast cancer relapseShortened overall survivalBaseline prior to treatmentNavigating practical challenges in immunotherapy for metastatic triple negative breast cancer
Licata L, Dieci M, De Angelis C, Marchiò C, Miglietta F, Cortesi L, Fabi A, Schmid P, Cortes J, Pusztai L, Bianchini G, Curigliano G. Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer. Cancer Treatment Reviews 2024, 128: 102762. PMID: 38776613, DOI: 10.1016/j.ctrv.2024.102762.Peer-Reviewed Original ResearchTriple-negative breast cancerBreast cancerMetastatic triple negative breast cancerManagement of breast cancer patientsTriple negative breast cancerApproval of immunotherapyImmune checkpoint inhibitorsNegative breast cancerBreast cancer patientsEveryday clinical practiceCheckpoint inhibitorsTumor typesCancer patientsClinical trialsCancer therapyImmunotherapyCancerClinical practicePositive resultsCliniciansTumorTherapyPatientsTrialsInhibitorsLong-Term Considerations for Young Breast Cancer Patients: Fertility, Sexual Health, and Quality of Life
Proussaloglou E, Lustberg M. Long-Term Considerations for Young Breast Cancer Patients: Fertility, Sexual Health, and Quality of Life. Current Breast Cancer Reports 2024, 16: 227-236. DOI: 10.1007/s12609-024-00548-z.Peer-Reviewed Original ResearchYoung breast cancer patientsSurvivorship careBreast cancer patientsEffectiveness of cancer careFamily planning concernsPost-partum careUnique survivorship needsQuality-of-life issuesBreast cancerQuality of lifeCancer patientsSurvivorship needsGenitourinary syndrome of menopauseCancer careDisease-free recurrenceAnti-estrogen therapyUnique group of patientsSexual healthGroup of patientsCareVaginal estrogenEndocrine therapyOverall survivalSummaryAdditional researchIatrogenic menopause2LBA LBA Oral Immune subtyping in the Response Predictive Subtypes (RPS) identifies a subset of triple negative (TN) early-stage breast cancer patients with a very low likelihood of response to neoadjuvant immunotherapy (IO): results from 5 IO arms of the I-SPY2 TRIAL
Wolf D, Yau C, Haan J, Wehkamp D, Witteveen A, Glas A, Campbell M, Nanda R, Chien J, Shatsky R, Isaacs C, Barcura A, Mittempergher L, Kuilman M, Yee D, DeMichele A, Perlmutter J, Pusztai L, Esserman L, van ’t Veer L. 2LBA LBA Oral Immune subtyping in the Response Predictive Subtypes (RPS) identifies a subset of triple negative (TN) early-stage breast cancer patients with a very low likelihood of response to neoadjuvant immunotherapy (IO): results from 5 IO arms of the I-SPY2 TRIAL. European Journal Of Cancer 2024, 200: 113953. DOI: 10.1016/j.ejca.2024.113953.Peer-Reviewed Original ResearchCINDERELLA Trial: validation of an artificial-intelligence cloud-based platform to improve the shared decision-making process and outcomes in breast cancer patients proposed for locoregional treatment
Bonci E, Kaidar-Person O, Antunes M, Ciani O, Cruz H, Di Micco R, Gentilini O, Gouveia P, Heil J, Kabata P, Freitas N, Gonçalves T, Romariz M, Martins H, Mavioso C, Mika M, Pfob A, Schinköthe T, Silva G, Cardoso M. CINDERELLA Trial: validation of an artificial-intelligence cloud-based platform to improve the shared decision-making process and outcomes in breast cancer patients proposed for locoregional treatment. European Journal Of Surgical Oncology 2024, 50: 107916. DOI: 10.1016/j.ejso.2023.107916.Peer-Reviewed Original ResearchBreast cancer patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply